Identification of a naturally processed HLA-Cw7-binding peptide that cross-reacts with HLA-A24-restricted ovarian cancer-specific CTLs.

Here, we describe an human leukocyte antigen (HLA)-A*24:02-restricted cytotoxic T-lymphocyte (CTL) clone, 1G3, established from naïve CD8(+) T-lymphocytes obtained from a healthy donor stimulated with HLA-modified TOV21G, an ovarian cancer cell line. The 1G3 clone responds not only to ovarian cancer cells in the context of HLA-A*24:02 but also to allogeneic HLA-Cw*07:02 molecules through cross-reactive T-cell receptor recognition. Expression screening using a complementary DNA library constructed from TOV21G messenger RNA revealed that this alloreactivity was mediated through the nine-mer peptide VRTPYTMSY, derived from RNA-binding motif protein 4. To our knowledge, this study presents the first example of the allorecognition of an HLA-Cw molecule by HLA-A-restricted T-cells, thereby revealing a naturally processed epitope peptide. These findings provide the structural bases for the allorecognition of human T-cells. In addition, this study suggests that unexpected alloresponses occur in certain HLA combinations, and further study is needed to understand the mechanisms of alloreactivity for better prediction of alloresponses in clinical settings.

[1]  A. Amir,et al.  Allo-HLA reactivity of virus-specific memory T cells is common. , 2010, Blood.

[2]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[3]  J. Yewdell,et al.  The binary logic of antigen processing and presentation to T cells , 1990, Cell.

[4]  D. Price,et al.  A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides* , 2011, The Journal of Biological Chemistry.

[5]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  H. Miyoshi,et al.  Autophagy Creates a CTL Epitope That Mimics Tumor-Associated Antigens , 2012, PloS one.

[7]  B. Morris,et al.  RBM4: a multifunctional RNA-binding protein. , 2009, The international journal of biochemistry & cell biology.

[8]  M. Tanimoto,et al.  Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. , 2004, Blood.

[9]  M. Kalos,et al.  Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. , 2013, Immunity.

[10]  Bent K Jakobsen,et al.  Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells , 2013, Science Translational Medicine.

[11]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[12]  M. Bonneville,et al.  Cross-Reactivity of Herpesvirus-Specific CD8 T Cell Lines Toward Allogeneic Class I MHC Molecules , 2010, PloS one.

[13]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[14]  L. Barber,et al.  The structural basis of T-cell allorecognition. , 2004, Tissue antigens.

[15]  T. Schumacher,et al.  T-cell-receptor gene therapy , 2002, Nature Reviews Immunology.

[16]  K. Rock,et al.  Antigen processing and presentation by the class I major histocompatibility complex. , 1996, Annual review of immunology.

[17]  S. Rowland-Jones,et al.  HLA‐C as a mediator of natural killer and T‐cell activation: spectator or key player? , 2011, Immunology.

[18]  Erhard Bieberich,et al.  Functional Pre- mRNA trans-Splicing of Coactivator CoAA and Corepressor RBM4 during Stem/Progenitor Cell Differentiation* , 2009, The Journal of Biological Chemistry.

[19]  James McCluskey,et al.  T cell allorecognition via molecular mimicry. , 2009, Immunity.

[20]  David Heckerman,et al.  Influence of HLA-C Expression Level on HIV Control , 2013, Science.

[21]  F. Ennis,et al.  Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. , 1997, Virology.

[22]  Paul M. Allen,et al.  Specificity of T-cell alloreactivity , 2007, Nature Reviews Immunology.

[23]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  K. Sugio,et al.  Identification of HLA‐A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung , 2006, International journal of cancer.

[25]  J. Drijfhout,et al.  Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. , 2011, Blood.

[26]  F. Kikkawa,et al.  An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. , 2013, Human immunology.

[27]  G. Oliveira,et al.  Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation , 2014, Immunological reviews.

[28]  T. Tsurumi,et al.  Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. , 2001, Blood.

[29]  H. Ikeda,et al.  Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. , 1997, Journal of immunology.

[30]  Philippa Marrack,et al.  A single T cell receptor bound to major histocompatibility complex class I and class II glycoproteins reveals switchable TCR conformers. , 2011, Immunity.

[31]  L. K. Ely,et al.  T cell allorecognition and MHC restriction--A case of Jekyll and Hyde? , 2008, Molecular immunology.

[32]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[33]  Adam Bagg,et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. , 2013, Blood.

[34]  K. Sugio,et al.  Identification of the HLA-Cw*0702-Restricted Tumor-Associated Antigen Recognized by a CTL Clone from a Lung Cancer Patient , 2005, Clinical Cancer Research.

[35]  K. Fujii,et al.  Rapid Determination of Epstein-Barr Virus–Specific CD8+T-Cell Frequencies by Flow Cytometry , 1999 .

[36]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[37]  M. Raffeld,et al.  Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Sugio,et al.  Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. , 2002, Chest.

[39]  Mark M Davis,et al.  How T cells 'see' antigen , 2005, Nature Immunology.